Even through JNJ's RSV-vaccine trial was officially still in progress, JNJ already had the relevant dataset when it made the decision to stop the trial, according to today's writeup by Evaluate Vantage.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”